Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Rank in Stocks #25865
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Share Price
$1.21
Market Cap
$45.55M
Change (1 day)
-2.43%
Change (1 year)
-34.60%
Country
US
Trade Metagenomi, Inc. Common Stock (MGX)

Category

Dividend history for Metagenomi, Inc. Common Stock (MGX)
Metagenomi, Inc. Common Stock (stock symbol: MGX) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Metagenomi, Inc. Common Stock (MGX) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
0.00%
US